6-K - MCUJF - Equibles

UNITED STATES

SECURITIESAND EXCHANGE COMMISSION

Washington,D.C. 20549

FORM 6-K

REPORT OFFOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THESECURITIES EXCHANGE ACT OF 1934

For the month of December 2020

Commission File Number: 001-31995

MEDICUREINC.

(Translation of registrant's name into English)

2-1250 Waverley Street

Winnipeg, MB Canada R3T 6C6

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F x Form 40-F o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes o No x

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 8a72____.

EXHIBITLIST

Exhibit	Title
99.1	Material Change Report dated December 21, 2020

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Medicure Inc.
	(Registrant)
Date: December 21, 2020	By:	/s/ Dr. Albert D. Friesen
		Dr. Albert D. Friesen
		Title: CEO

Exhibit 99.1

MATERIAL CHANGE REPORT

PURSUANT TO SECTION 7.1 OF NATIONAL INSTRUMENT51-102

1.	Name and Address of Company:

Medicure Inc. (“Medicure” or the “Corporation”)

2 – 1250 Waverley Street

Winnipeg, Manitoba R3T 6C6

2.	Date of Material Change:

December 17, 2020

3.	News Release:

A press release with respect to the material change described herein was issued on December 17, 2020 and filed on SEDAR.

4.	Summary of Material Change:

Medicure announced that, through its wholly-owned U.S. subsidiary, Medicure Pharma Inc., it entered into a definitive agreement on December 15, 2020, to acquire 100% of Marley Drug, Inc ("Marley"), a leading specialty pharmacy serving more than 30,000 customers across the United States, from an arms-length third-party, for an upfront payment on closing of USD $6.3 million, subject to certain holdbacks, as well as additional payments based on future performance of Marley. Marley generated unaudited revenue and EBITDA of approximately USD $7.0 million and over USD $1.7 million for the 12-month period ended October 31, 2020, respectively.

5.	Full Description Of Material Change:

See Attached Schedule “A”.

6.	Reliance on subsection 7.1(2) of National Instrument 51-102:

Not Applicable.

7.	Omitted Information:

Not Applicable.

8.	Executive Officer:

For further information contact James Kinley, Chief Financial Officer of Medicure Inc. (204) 487-7412.

Dated at Winnipeg, Manitoba this 21^st^ day of December 2020

MEDICURE INC.

Per: “James Kinley”

Chief Financial Officer

SCHEDULE “A”

Medicure Enters the US OnlinePharmacy World with Acquisition of Marley Drug

Winnipeg, Canada, December 17, 2020 – Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, today announced that, through its wholly-owned U.S. subsidiary, Medicure Pharma Inc., it entered into a definitive agreement on December 15, 2020, to acquire 100% of Marley Drug, Inc ("Marley"), a leading specialty pharmacy serving more than 30,000 customers across the United States, from an arms-length third-party, for an upfront payment on closing of USD $6.3 million, subject to certain holdbacks, as well as additional payments based on future performance of Marley. Marley generated unaudited revenue and EBITDA of approximately USD $7.0 million and over USD $1.7 million for the 12-month period ended October 31, 2020, respectively.

Marley provides excellent customer service, cost competitive medications, immediate direct to patient delivery, and is licensed in all 50 states, Washington D.C. and Puerto Rico. Its advanced operating systems include automated pill dispensing, an extended supply generic drug program, and an effective customer communication system. Marley has been successful in marketing directly to customers, providing access to medications without the need for insurance, and building a nationwide customer base.

"This transaction marks the start of an exciting new chapter for our company," said Albert D. Friesen, PhD, Chief Executive Officer of Medicure and Chair of its Board of Directors. "We look forward to welcoming the Marley specialty pharmacy team and dedicated customers and physicians. The combined business will be well positioned to strengthen our existing national platforms, accelerate growth of Medicure’s primary care drug, ZYPITAMAG^®^ (pitavastatin) tablets, realize material synergies and generate substantial shareholder value.” The Company remains focused on the sale and commercial development of its existing products.

Medicure intends to finance the acquisition of Marley with a term loan from a Canadian commercial bank.

About Medicure Inc.

Medicure is a pharmaceutical company focused on the development and commercialization of therapies for the U.S. cardiovascular market. The present focus of the Company is the marketing and distribution of AGGRASTAT^®^ (tirofiban hydrochloride) injection and ZYPITAMAG^®^ (pitavastatin) tablets in the United States, where they are sold through the Company’s U.S. subsidiary, Medicure Pharma Inc. For more information on Medicure please visit www.medicure.com. For additional information about ZYPITAMAG^®^, refer to the full Prescribing Information.

About Marley

Independently owned, Marley was established in 2003 by Dr. David Marley, PharmD to offer accessible, cost effective and high-quality pharmacy services to employers and other health care consumers in North Carolina. In 2011, Marley expanded its reach, serving all 50 states and Washington D.C. with their Extended Supply mail order drug program. Marley is committed to improving the health status of their patients and the communities they serve while reducing overall health care costs for employers and other health care consumers. For more information visit www.marleydrug.com. To learn more about The Extended Supply Generic Drug Program call 800.286.6781 or email marleydrug@bellsouth.net.

To be added to Medicure’s e-mail list,please visit: http://medicure.mediaroom.com/alerts

Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy oraccuracy of this release.

Forward Looking Information: Statementscontained in this press release that are not statements of historical fact, including, without limitation, statements containingthe words "believes", "may", "plans", "will", "estimates", "continues","anticipates", "intends", "expects" and similar expressions, may constitute "forward-lookinginformation" within the meaning of applicable Canadian and U.S. federal securities laws (such forward-looking informationand forward-looking statements are hereinafter collectively referred to as "forward-looking statements"). Forward-lookingstatements, include estimates, analysis and opinions of management of the Company made in light of its experience and its perceptionof trends, current conditions and expected developments, as well as other factors which the Company believes to be relevant andreasonable in the circumstances. Inherent in forward-looking statements are known and unknown risks, uncertainties and other factorsbeyond the Company's ability to predict or control that may cause the actual results, events or developments to be materially differentfrom any future results, events or developments expressed or implied by such forward-looking statements, and as such, readers arecautioned not to place undue reliance on forward-looking statements. Such risk factors include, among others, the Company's futureproduct revenues, expected results, including revenue and growth from Marley, expected future growth in revenues, stage of development,additional capital requirements, risks associated with the completion and timing of clinical trials and obtaining regulatory approvalto market the Company's products, the ability to protect its intellectual property, dependence upon collaborative partners, changesin government regulation or regulatory approval processes, and rapid technological change in the industry. Such statements arebased on a number of assumptions which may prove to be incorrect, including, but not limited to, assumptions about: general businessand economic conditions; the impact of changes in Canadian-US dollar and other foreign exchange rates on the Company's revenues,costs and results; the timing of the receipt of regulatory and governmental approvals for the Company's research and developmentprojects; the availability of financing for the Company's commercial operations and/or research and development projects, or theavailability of financing on reasonable terms; results of current and future clinical trials; the uncertainties associated withthe acceptance and demand for new products and market competition. The foregoing list of important factors and assumptions is notexhaustive. The Company undertakes no obligation to update publicly or otherwise revise any forward-looking statements or the foregoinglist of factors, other than as may be required by applicable legislation. Additional discussion regarding the risks and uncertaintiesrelating to the Company and its business can be found in the Company's other filings with the applicable Canadian securities regulatoryauthorities or the US Securities and Exchange Commission, and in the "Risk Factors" section of its Form 20F for the yearended December 31, 2019.

For more information, please contact:

James Kinley

Chief Financial Officer

Tel. 888-435-2220

Fax 204-488-9823

E-mail: info@medicure.com